Mostrar el registro sencillo del ítem

Seguridad de la vapoenucleación de próstata con láser Thulium en pacientes anticoagulados, experiencia de 7 años en centro de tercer nivel

dc.contributor.advisorSalazar Rey, Milton
dc.contributor.advisorCamacho López, Paul Anthony
dc.contributor.authorRodríguez Piedrahita, Héctor Mauricio
dc.coverage.spatialColombiaspa
dc.date.accessioned2022-07-11T18:42:36Z
dc.date.available2022-07-11T18:42:36Z
dc.date.issued2022-06-28
dc.identifier.urihttp://hdl.handle.net/20.500.12749/16893
dc.description.abstractEn la actualidad se considera la resección transuretral de próstata (RTUp) como terapia gold estándar para la HPB, sin embargo, esta técnica presenta una tasa de morbilidad de hasta 30% al 46% en pacientes con anticoagulación. La inversión en la pirámide poblacional conlleva a una elevación en la incidencia de enfermedades crónicas, lo cual incrementa el uso de terapias anticoagulantes o antiagregantes plaquetarios en los pacientes con HPB, lo que genera la necesidad de establecer un lineamiento de manejo en este grupo de pacientes que requiere manejo quirúrgico. La técnica de vapoenucleación de próstata con láser thulium (ThuVARP) debido a sus características, es la técnica recomendada por la EAU en el manejo quirúrgico en este grupo de pacientes, la cual presenta en algunos reportes una menor tasa de complicaciones relacionadas a sangrado. Se encuentra literatura limitada que determinen factores de riesgo asociados a complicaciones en estos pacientes.spa
dc.description.tableofcontentsRESUMEN INTRODUCCIÓN 1. JUSTIFICACIÓN 2. OBJETIVOS 2.1 OBJETIVO GENERAL 2.2 OBJETIVOS ESPECÍFICOS 3. MARCO TEÓRICO Y ESTADO DEL ARTE 4. METODOLOGÍA 4.1 Diseño 4.2 Universo 4.3 Población Objeto 4.4 Muestra 4.5 Criterios de Inclusión y Exclusión 4.6 Variables 4.7 Manejo del paciente y obtención de información. 4.8 Plan de Análisis 5. CONSIDERACIONES ÉTICAS 6. RESULTADOS 7. DISCUSIÓN 8. CONCLUSIONES 9. BIBLIOGRAFÍAspa
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.titleSeguridad de la vapoenucleación de próstata con láser Thulium en pacientes anticoagulados, experiencia de 7 años en centro de tercer nivelspa
dc.title.translatedSafety of prostate vapoenucleation with Thulium laser in anticoagulated patients, 7-year experience in a tertiary care centerspa
dc.degree.nameEspecialista en Urologíaspa
dc.publisher.grantorUniversidad Autónoma de Bucaramanga UNABspa
dc.rights.localAbierto (Texto Completo)spa
dc.publisher.facultyFacultad Ciencias de la Saludspa
dc.publisher.programEspecialización en Urologíaspa
dc.description.degreelevelEspecializaciónspa
dc.type.driverinfo:eu-repo/semantics/masterThesis
dc.type.localTesisspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdcc
dc.subject.keywordsMedical sciencesspa
dc.subject.keywordsHealth sciencesspa
dc.subject.keywordsUrologyspa
dc.subject.keywordsMedicinespa
dc.subject.keywordsTransurethral resectionspa
dc.subject.keywordsChronic diseasesspa
dc.subject.keywordsAnticoagulationspa
dc.subject.keywordsHematologic agentsspa
dc.subject.keywordsBlood coagulationspa
dc.subject.keywordsHyperplasiaspa
dc.subject.keywordsProstate diseasesspa
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga - UNABspa
dc.identifier.reponamereponame:Repositorio Institucional UNABspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.relation.references1. Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015;22 Suppl 1:1-6.spa
dc.relation.references2. Gravas S, Bach T, Bachmann A, Drake M, Gacci M, Gratzke C, et al. Guidelines on the Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO).spa
dc.relation.references3. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, et al. The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia. N Engl J Med. 2003 Dec 18;349(25):2387–98spa
dc.relation.references4. Raber M, Buchholz NNP, Vercesi A, et al. Thulium laser enucleation of the prostate (Thulep): Results, complications, and risk factors in 139 consecutive cases. Arab Journal of Urology. 2018;16(4):411-416.spa
dc.relation.references5. Sener TE, Butticè S, Macchione L, et al. Thulium laser vaporesection of the prostate: Can we operate without interrupting oral antiplatelet/anticoagulant therapy? Investig Clin Urol. 2017;58(3):192spa
dc.relation.references6. S. Gravas (Chair), J.N. Cornu, M. Gacci, C. Gratzke, T.R.W. Herrmann, C. Mamoulakis, M. Rieken, M.J. Speakman, K.A.O. Tikkinen. Management of Non-neurogenic Male LUTS. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2021. ISBN 978-94-92671-13-4.spa
dc.relation.references7. Foster HE, Barry MJ, Dahm P, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. J Urol 2018; 11: 43201–43206spa
dc.relation.references8. Heiman J, Large T, Krambeck A. Best practice in the management of benign prostatic hyperplasia in the patients requiring anticoagulation. Ther Adv Urol. 2018, Vol. 10(12) 431–436spa
dc.relation.references9. Musi G, Mistretta FA, Marenghi C, et al. Thulium laser treatment of upper urinary tract carcinoma: a multi-institutional analysis of surgical and oncological outcomes. Journal of Endourology. 2018;32(3):257-263.spa
dc.relation.references10. Traxer, O.;Corrales,M. Managing Urolithiasis with Thulium Fiber Laser: Updated Real-Life Results—A Systematic Review. J. Clin. Med.2021,10,3390. https://doi.org/ 10.3390/jcm10153390spa
dc.relation.references11. Michalak J, Tzou D, Funk J. HoLEP: the gold standard for the surgical management of BPH in the 21(St) Century. Am J Clin Exp Urol. 2015;3(1):3642.spa
dc.relation.references12. Zhang F, Shao Q, Herrmann TRW, Tian Y, Zhang Y. Thulium laser versus holmium laser transurethral enucleation of the prostate: 18-month follow-up data of a single center. Urologuny. 2012;79(4):869-874spa
dc.relation.references13. Xia SJ, Zhang YN, Lu J, Sun XW, Zhang J, Zhu YY, et al. Thulium laser resection of prostate-tangerine technique in treatment of benign prostate hyperplasia. Zhonghua yi xue za zhi. 2005 Nov;85(45):3225-3228spa
dc.relation.references14. Maruccia, S., Fulgheri, I., Montanari, E. et al. Nomenclature in thulium laser treatment of benign prostatic hyperplasia: it’s time to pull the rabbit out of the hat. Lasers Med Sci (2021)spa
dc.relation.references15. Bach T, Xia SJ, Yang Y, Mattioli S, Watson GM, Gross AJ, et al. Thulium:YAG 2 μm cw laser prostatectomy: where do we stand? World J Urol. 2010 Apr 5;28(2):163–8.spa
dc.relation.references16. Hauser S, Rogenhofer S, Ellinger J, Strunk T, Müller SC, Fechner G. Thulium laser (Revolix) vapoenucleation of the prostate is a safe procedure in patients with an increased risk of hemorrhage. Urol Int. 2012;88(4):390-394spa
dc.relation.references17. DANE –Departamento Administrativo Nacional de Estadística– (2018). Censo General 2018 [documento en línea]. Disponible en https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-ypoblacion/censo-nacional-de-poblacion-y-vivenda-2018/informacion-tecnica [Consultado el 01 de septiembre de 2021].spa
dc.relation.references18. Teichmann HO, Herrmann TR, Bach T. Technical aspects of lasers in urology. World J Urol 2007; 25: 221–5spa
dc.relation.references19. Critical review of lasers in benign prostatic hyperplasia (BPH). Stavros Gravas, Alexander Bachmann, Oliver Reich et al. BJU International Volume 107, Issue 7, Version of Record online: 25 MAR 2011. Reviewed 26-02-2018spa
dc.relation.references20. Fried NM. High-power laser vaporization of the canine prostate using a 110 W Thulium fiber laser at 1.91 microm. Lasers Surg Med 2005;36:52-6.spa
dc.relation.references21. Cornu JN. Bipolar, Monopolar, Photovaporization of the Prostate, or Holmium Laser Enucleation of the Prostate. How to Choose What’s Best?. Urol Clin N Am 43. 2016; 377–84spa
dc.relation.references22. Netsch C, Herrmann TRW, Bozzini G, Berti L, Gross AJ, Becker B. Recent evidence for anatomic endoscopic enucleation of the prostate (Aeep) in patients with benign prostatic obstruction on antiplatelet or anticoagulant therapy. World J Urol. Published online March 15, 2021spa
dc.relation.references23. Taylor K, Filgate R, Guo DY, et al. A retrospective study to assess the morbidity associated with transurethral prostatectomy in patients on antiplatelet or anticoagulant drugs. BJU Int 2011; 108 (Suppl. 2): 45–50spa
dc.relation.references24. Tang K, Xu Z, Xia D, Ma X, Guo X, Guan W, et al. Early Outcomes of Thulium Laser Versus Transurethral Resection of the Prostate for Managing Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis of Comparative Studies. J Endourol. 2014 Jan;28(1):65–72.spa
dc.relation.references25. Lourenco T, Pickard R, Vale L, Grant A, Fraser C, MacLennan G, et al. Alternative approaches to endoscopic ablation for benign enlargement of the prostate: systematic review of randomised controlled trials. BMJ. 2008 Jun 30;337(jun30 1):a449–a449spa
dc.relation.references26. Hartung FO, et al. Holmium Versus Thulium Laser Enucleation of the Prostate: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol Focus (2021). Article in press. https://doi.org/10.1016/j.euf.2021.03.024spa
dc.relation.references27. Castellani D, Di Rosa M, Gasparri L, Pucci M, Dellabella M. Thulium laser vapoenucleation of the prostate (Thuvep) in men at high cardiovascular risk and on antithrombotic therapy: a single-center experience. JCM. 2020;9(4):917.spa
dc.relation.references28. Charbonneau H, Pasquié M, Peyronnet B, et al. Stopping or maintaining oral anticoagulation in patients undergoing photoselective vaporization of the prostate (Soap) surgery for benign prostate obstruction: study protocol for a multicentre randomized controlled trial. Trials. 2018;19(1):705.spa
dc.relation.references29. Tiret L, Hatton F, Desmonts JM, Vourc’h G. Prediction of outcome of anaesthesia in patients over 40 years: A multifactorial risk index. Stat Med. 1988;7:947–54spa
dc.relation.references30. Netsch C, Stoehrer M, Brüning M, et al. Safety and effectiveness of Thulium VapoEnucleation of the prostate (Thuvep) in patients on anticoagulant therapy. World J Urol. 2014;32(1):165-172spa
dc.contributor.cvlacSalazar Rey, Milton [0001489804]spa
dc.contributor.cvlacCamacho López, Paul Anthony [0000323578]spa
dc.contributor.googlescholarCamacho López, Paul Anthony [u8d7_QAAAAJ]spa
dc.contributor.orcidSalazar Rey, Milton [0000-0002-1316-4149]spa
dc.contributor.orcidCamacho López, Paul Anthony [0000-0002-6233-9582]spa
dc.contributor.researchgateSalazar Rey, Milton [Milton-Salazar-Rey-31568627]spa
dc.contributor.researchgateCamacho López, Paul Anthony [Paul_Camacho_Lopez]spa
dc.subject.lembUrologíaspa
dc.subject.lembMedicinaspa
dc.subject.lembCiencias médicasspa
dc.subject.lembAgentes hematológicosspa
dc.subject.lembCoagulación sanguineaspa
dc.subject.lembHiperplasiaspa
dc.subject.lembEnfermedades de la próstataspa
dc.identifier.repourlrepourl:https://repository.unab.edu.cospa
dc.description.abstractenglishIt is currently considered transurethral Resection of the prostate to be a gold standard therapy for benign prosthetic hyperplasia, however this technique presents a morbidity rate of up to 30% to 46% In patients with anticoagulation. The inversion of the population pyramid brings with it an elevation in the incidence of chronic diseases, which in turn increases the use of anticoagulant therapy or antiplatelet aggregation in patients with benign prostatic hyperplasia thus generating a need to stablish a pattern of treatment in these patients which requires surgical treatment. Due to its characteristics, vapoenucleation of the prostate using thulium laser is the technique recommended by the EAU when surgically handling these groups of patients, which in some reports present a lower rate of complications related to bleeding. There isn’t enough written material on the topic to fully determine the risk factors associated with these complications in these patients.spa
dc.subject.proposalCiencias de la saludspa
dc.subject.proposalResección transuretralspa
dc.subject.proposalEnfermedades crónicasspa
dc.subject.proposalAnticoagulaciónspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TM
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.contributor.apolounabCamacho López, Paul Anthony [paul-anthony-camacho-lópez]
dc.coverage.campusUNAB Campus Bucaramangaspa
dc.description.learningmodalityModalidad Presencialspa
dc.contributor.linkedinCamacho López, Paul Anthony [paulcamachomdepi]


Ficheros en el ítem

Thumbnail
Nombre:
2022_Tesis_Hector_Mauricio_Rod ...
Tamaño:
388.4Kb
Formato:
PDF
Descripción:
Tesis
Ver/
Thumbnail
Nombre:
2022_Licencia_Hector_Mauricio_ ...
Tamaño:
72.53Kb
Formato:
PDF
Descripción:
Licencia
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 2.5 Colombia
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 2.5 Colombia